See more : Jilin Forest Industry Co., Ltd. (600189.SS) Income Statement Analysis – Financial Results
Complete financial analysis of KORU Medical Systems, Inc. (KRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KORU Medical Systems, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Lakala Payment Co., Ltd. (300773.SZ) Income Statement Analysis – Financial Results
- Fincantieri S.p.A. (FNCNF) Income Statement Analysis – Financial Results
- Vardhman Textiles Limited (VTL.NS) Income Statement Analysis – Financial Results
- SIMMTECH Co., Ltd. (222800.KQ) Income Statement Analysis – Financial Results
- Pluxee N.V. (PLX.PA) Income Statement Analysis – Financial Results
KORU Medical Systems, Inc. (KRMD)
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.52M | 27.90M | 23.49M | 24.18M | 23.16M | 17.35M | 15.98M | 12.29M | 12.25M | 11.24M | 8.70M | 7.76M | 6.39M | 4.92M | 3.77M | 3.44M | 2.35M | 1.73M | 1.75M | 1.56M | 1.53M | 1.66M | 1.76M | 2.09M | 2.07M |
| Cost of Revenue | 11.81M | 12.53M | 9.72M | 9.24M | 8.31M | 6.54M | 6.52M | 4.72M | 4.64M | 4.56M | 3.39M | 2.82M | 2.25M | 1.66M | 1.26M | 1.24M | 899.98K | 663.51K | 728.52K | 726.46K | 723.56K | 959.54K | 1.33M | 1.11M | 1.13M |
| Gross Profit | 16.71M | 15.37M | 13.77M | 14.94M | 14.85M | 10.81M | 9.46M | 7.57M | 7.60M | 6.69M | 5.31M | 4.94M | 4.14M | 3.26M | 2.51M | 2.20M | 1.45M | 1.07M | 1.02M | 833.76K | 804.83K | 697.02K | 427.94K | 978.94K | 939.85K |
| Gross Profit Ratio | 58.59% | 55.09% | 58.62% | 61.78% | 64.13% | 62.29% | 59.20% | 61.57% | 62.08% | 59.47% | 61.04% | 63.69% | 64.77% | 66.32% | 66.53% | 63.85% | 61.67% | 61.75% | 58.27% | 53.44% | 52.66% | 42.08% | 24.33% | 46.93% | 45.50% |
| Research & Development | 5.74M | 4.96M | 2.47M | 1.30M | 740.48K | 241.12K | 60.70K | 237.49K | 207.28K | 468.15K | 218.15K | 147.58K | 90.33K | 35.52K | 27.92K | 22.44K | 59.93K | 42.03K | 41.82K | 44.03K | 42.19K | 40.27K | 40.84K | 35.34K | 80.94K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.37M | 20.61M | 17.86M | 12.03M | 9.77M | 8.20M | 7.91M | 7.77M | 5.94M | 4.79M | 3.85M | 3.54M | 2.66M | 1.97M | 1.70M | 1.31M | 1.13M | 993.42K | 984.63K | 1.07M | 876.39K | 827.87K | 635.53K | 827.99K | 1.01M |
| Other Expenses | 870.39K | 0.00 | 679.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 26.98M | 26.15M | 20.80M | 13.74M | 10.85M | 8.75M | 7.97M | 8.31M | 6.42M | 5.54M | 4.30M | 3.88M | 2.85M | 2.07M | 1.79M | 1.42M | 1.25M | 1.09M | 1.11M | 1.19M | 1.05M | 949.57K | 802.20K | 1.08M | 1.18M |
| Cost & Expenses | 38.79M | 38.68M | 30.52M | 22.98M | 19.16M | 15.29M | 14.49M | 13.03M | 11.07M | 10.10M | 7.69M | 6.70M | 5.10M | 3.73M | 3.05M | 2.66M | 2.15M | 1.76M | 1.83M | 1.92M | 1.77M | 1.91M | 2.13M | 2.19M | 2.30M |
| Interest Income | 561.33K | 145.59K | 13.08K | 42.40K | 80.66K | 28.10K | 0.00 | 2.94K | 0.00 | 5.62K | 7.43K | 8.08K | 12.85K | 8.72K | 1.35K | 8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 3.41K | 512.00 | 4.55K | 28.28K | 31.54K | 36.39K | 47.50K | 51.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 870.39K | 587.14K | 463.13K | 418.60K | 340.23K | 309.26K | 308.71K | 300.61K | 271.57K | 283.88K | 232.96K | 190.97K | 103.98K | 65.77K | 64.80K | 79.36K | 68.20K | 60.43K | 79.09K | 81.82K | 80.55K | 81.44K | 84.84K | 84.97K | 87.80K |
| EBITDA | -9.40M | -10.19M | -6.57M | 1.61M | 4.34M | 2.37M | 1.88M | -474.20K | 1.42M | 1.36M | 1.24M | 1.25M | 1.42M | 1.30M | 774.76K | 855.89K | 261.71K | 38.29K | -9.16K | -277.54K | -165.09K | -171.12K | -289.42K | -17.38K | -149.54K |
| EBITDA Ratio | -32.96% | -36.40% | -27.84% | 16.71% | 33.36% | 18.94% | 11.22% | -3.52% | 11.79% | 12.78% | 14.35% | 16.25% | 22.00% | 26.37% | 20.87% | 24.96% | 11.15% | 12.28% | 4.55% | -17.79% | -7.44% | -10.33% | -14.12% | 5.54% | -26.45% |
| Operating Income | -10.27M | -10.78M | -7.03M | -1.25M | 585.68K | 1.16M | 1.48M | -736.25K | 1.18M | 1.15M | 1.01M | 1.06M | 1.29M | 1.19M | 721.52K | 779.01K | 193.51K | -22.14K | -88.25K | -359.35K | -245.64K | -252.56K | -374.26K | -102.35K | -237.34K |
| Operating Income Ratio | -36.01% | -38.65% | -29.93% | -5.19% | 2.53% | 6.71% | 9.29% | -5.99% | 9.65% | 10.20% | 11.58% | 13.68% | 20.17% | 24.28% | 19.11% | 22.65% | 8.24% | -1.28% | -5.06% | -23.03% | -16.07% | -15.25% | -21.28% | -4.91% | -11.49% |
| Total Other Income/Expenses | 496.40K | 105.71K | 665.09K | 60.52K | 110.74K | 12.41K | 85.18K | -40.45K | -38.81K | -72.86K | 2.78K | -24.29K | -7.97K | -1.71K | -59.06K | -54.16K | -193.51K | -232.59K | -129.56K | -40.14K | -31.53K | -14.84K | -11.24K | -2.11K | 237.34K |
| Income Before Tax | -9.77M | -10.68M | -6.36M | -1.19M | 696.42K | 1.18M | 1.57M | -776.70K | 1.14M | 1.07M | 1.01M | 1.04M | 1.28M | 1.19M | 662.46K | 724.86K | 0.00 | -254.72K | -217.82K | -399.49K | -277.17K | -267.39K | -385.50K | -104.46K | 159.46K |
| Income Before Tax Ratio | -34.27% | -38.27% | -27.09% | -4.94% | 3.01% | 6.78% | 9.82% | -6.32% | 9.33% | 9.56% | 11.62% | 13.37% | 20.05% | 24.25% | 17.55% | 21.08% | 0.00% | -14.68% | -12.48% | -25.60% | -18.13% | -16.14% | -21.92% | -5.01% | 7.72% |
| Income Tax Expense | 3.97M | -2.01M | -1.80M | 17.80K | 132.07K | 266.38K | 483.08K | -241.70K | 359.71K | 321.42K | 307.02K | 312.35K | 465.29K | 489.03K | -226.98K | -306.00K | 196.01K | 232.59K | 129.56K | 1.40K | 831.00 | 800.00 | 572.00 | 2.11K | -487.64K |
| Net Income | -13.74M | -8.66M | -4.56M | -1.21M | 564.35K | 910.57K | 1.09M | -535.00K | 782.86K | 753.12K | 703.43K | 725.76K | 815.89K | 704.09K | 889.44K | 1.03M | -2.50K | -254.72K | -217.82K | -400.89K | -278.00K | -268.19K | -386.08K | -104.46K | 250.30K |
| Net Income Ratio | -48.18% | -31.05% | -19.42% | -5.01% | 2.44% | 5.25% | 6.80% | -4.35% | 6.39% | 6.70% | 8.09% | 9.35% | 12.77% | 14.31% | 23.56% | 29.97% | -0.11% | -14.68% | -12.48% | -25.69% | -18.19% | -16.19% | -21.95% | -5.01% | 12.12% |
| EPS | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| EPS Diluted | -0.30 | -0.19 | -0.10 | -0.03 | 0.01 | 0.02 | 0.03 | -0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 | 0.00 | 0.01 |
| Weighted Avg Shares Out | 45.60M | 45.00M | 44.39M | 41.93M | 38.78M | 38.13M | 37.87M | 37.83M | 37.99M | 37.63M | 36.66M | 36.01M | 34.25M | 36.24M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 20.63M |
| Weighted Avg Shares Out (Dil) | 45.60M | 45.00M | 44.39M | 41.93M | 39.06M | 38.92M | 38.39M | 37.88M | 37.99M | 37.63M | 36.66M | 36.04M | 35.10M | 36.85M | 35.38M | 34.83M | 32.68M | 29.87M | 26.47M | 22.70M | 23.54M | 23.50M | 23.50M | 23.35M | 23.12M |
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large...
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global...
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of...
KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Call Transcript
KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference...
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first...
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first...
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to...
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the...
Source: https://incomestatements.info
Category: Stock Reports